Lyon, France (ots/PRNewswire) -
- Addition of fourth influenza virus strain aims to increase
protection
against influenza -
Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur,
announced today that it has submitted a decentralized marketing
authorization application in Europe for a 'Quadrivalent' influenza
vaccine, a new advanced seasonal flu vaccine.
The 'Quadrivalent' vaccine, developed by Sanofi Pasteur, is expected
to help protect people from four different strains of seasonal
influenza viruses. Currently available flu vaccines protect against
three strains of flu viruses. By including a fourth influenza strain,
the new seasonal flu vaccine could help further reduce influenza
disease and influenza-related complications, hospitalizations and
deaths.
"This filing clearly demonstrates our commitment to providing
advanced vaccine solutions to help improve disease prevention in
Europe," said Jean Paul Kress, President of Sanofi Pasteur MSD. "We
believe that quadrivalent flu vaccines will become the new standard
for the prevention of seasonal flu."
The new flu vaccine has been submitted for licences in Europe under
the decentralized approval process, with France acting as the
"Reference Member State" for the review of the licence dossier.
Once approved, the new quadrivalent vaccine will be commercialized in
Western European countries by Sanofi Pasteur MSD and in Eastern
European countries by Sanofi Pasteur, the vaccine division of Sanofi.
About Sanofi Pasteur MSD http://www.spmsd.com
Sanofi Pasteur MSD is a joint venture between Sanofi Pasteur, the
vaccine division of Sanofi, and Merck, known as MSD outside the USA
and Canada. Combining innovation and expertise, Sanofi Pasteur MSD is
the only company in Europe dedicated exclusively to vaccines. Sanofi
Pasteur MSD is able to draw on the research expertise of Sanofi
Pasteur and Merck to focus on the development of new vaccines for
Europe to improve the acceptability, efficacy and tolerability of
vaccination.
ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN
